Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00PEH
|
|||
| Former ID |
DCL000792
|
|||
| Drug Name |
Eltrombopag
|
|||
| Synonyms |
Eltrombopag [INN]; SB 497115; SB497115; SB-497115; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime; Thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-(9CI); (E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombocytopenia [ICD-11: 3B64] | Approved | [1], [2] | |
| Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10; ICD-10: D69.3; ICD-9: 287.31] | Phase 3 | [1], [3] | ||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H22N4O4
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
|
|||
| InChI |
1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)
|
|||
| InChIKey |
SVOQIEJWJCQGDQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 496775-61-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14808156, 29195841, 34806226, 44944248, 57373520, 76939526, 85853055, 93581192, 99006117, 123051088, 124772070, 126667018, 126731321, 135196778, 136367954, 136376451, 137206169, 137617354, 143498067, 144115937, 152059665, 152236438, 152344172, 162037592, 162201758, 162262104, 174476496, 175266113, 175427059, 176485025, 180371853, 188899541, 210275214, 210280853, 223671302, 226526630, 226566011, 226566012, 242060270, 242084108, 249823455, 250203595, 251894921, 251971165, 252058465, 252215343
|
|||
| ChEBI ID |
CHEBI:85010
|
|||
| ADReCS Drug ID | BADD_D00759 ; BADD_D00760 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [4] | |||
| Description | Eltrombopag can be metabolized by gut microbiota. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thrombopoietin receptor (MPL) | Target Info | Agonist | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| WikiPathways | Platelet Aggregation (Plug Formation) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6961). | |||
| REF 2 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | |||
| REF 3 | Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. | |||
| REF 4 | The metabolic effect of gut microbiota on drugs. Drug Metab Rev. 2020 Feb;52(1):139-156. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.